[1] Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis.Nat Rev Dis Primers, 2018,4:18017.
[2] Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology, 2020[ahead of print] .
[3] Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut, 2020,69(3):569-577.
[4] Liwinski T, Casar C, Ruehlemann MC, et al. A disease-specific decline of the relative abundance ofbifidobacterium in patients with autoimmune hepatitis. Aliment Pharmacol Ther, 2020,51(12):1417-1428.
[5] Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy.Gut 2018,67(3):534-541.
[6] Chen W, Wei Y, Xiong A, et al. Comprehensiveanalysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis. Clin Rev Allergy Immunol, 2020,58(1):25-38.
[7] Loftus EV, Jr Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut, 2005,54:91-96.
[8] Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol,2019,4:492-503.
[9] Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut, 2017,66:611–619.
[10] Ruhlemann MC, Heinsen FA, Zenouzi R, et al. Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut,2017,66:753–754.
[11] Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut, 2016,65:1681–1689.
[12] Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science, 2018,359(6380):1156-1161.
[13] Cai W, Ran Y, Li Y, et al. Intestinal microbiome and permeability in patients with autoimmune hepatitis. Best Pract Res Clin Gastroenterol, 2017,31:669-673.
[14] Fussey SP, Ali ST, Guest JR,et al. Reactivity of primary biliary cirrhosis sera with Escherichia coli dihy-drolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc Natl Acad Sci USA, 1990,87:3987-3991.
[15] Bogdanos DP, Baum H, Okamoto M, et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic.Hepatology, 2005,42:458-465.
[16] Terjung B, Söhne J, Lechtenberg B, et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ.Gut,2010,59:808-816.
[17] Melum E, Franke A, Schramm C,et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet, 2011, 43: 17–19.
[18] Rupp C, Friedrich K, Folseraas T, et al. Fut2 genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis. Aliment Pharmacol Ther, 2014, 39: 873–882.
[19] Janse M, Lamberts LE, Franke L, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology, 2011, 53: 1977–1985.
[20] Wannhoff A, Rupp C, Friedrich K, et al. Inflammation but not biliary obstruction is associated with carbohydrate antigen 19-9 levels in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol, 2015, 13: 2372–2379.
[21] Lamas B, Richard ML, Leducq V, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med, 2016,22: 598–605.
[22] Trivedi PJ, Bruns T, Ward S, et al. Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. J Autoimmun, 2016, 68: 98–104.
[23] Trivedi PJ, Tickle J, Vesterhus MN, et al. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate- dependent manner. Gut, 2017, 67: 1084–1103.
[24] Henriksen EK, Jorgensen KK, Kaveh F, et al. Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.J Hepatol, 2017, 66: 116–122.
[25] Moro-Sibilot L, Blanc P, Taillardet M, et al. Mouse and human liver contain immunoglobulin A-secreting cells originating from Peyer's patches and directed against intestinal antigens. Gastroenterology, 2016, 151: 311–323.
[26] Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.Science, 2018,360(6391):eaan5931.
[27] Nevens F, Andreone P, Mazzella G, et al. Aplacebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med, 2016,375(7):631-643.
[28] Vuerich M, Harshe R, Frank LA, et al. Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis. J Hepatol, 2020[ahead of print] .
[29] Bachem A, Makhlouf C, Binger KJ, et al. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8+ T Cells.Immunity, 2019,51(2):285-297.
[30] Carriche GM, Almeida L, Stüve P, et al. Regulating T-cell differentiation through the polyamine spermidine. J Allergy Clin Immunol, 2020S[ahead of print] .
[31] Chen S, Henderson A, Petriello MC, et al. Trimethylamine N-oxide binds and activates PERK to promote metabolic dysfunction. Cell Metab, 2019,30(6):1141-1151.
[32] Zhao M, Zhao L, Xiong X, et al. TMAVA, ametabolite of intestinal microbes, is increased in plasma from patients with liver steatosis, inhibits γ-butyrobetaine hydroxylase, and exacerbates fatty liver in mice. Gastroenterology, 2020,158(8):2266-2281. |
